Standard-dose and short-term corticosteroid therapy in immunoglobulin-resistant Kawasaki disease

Clin Pediatr (Phila). 2005 Jun;44(5):423-6. doi: 10.1177/000992280504400507.

Abstract

Six patients with Kawasaki disease (KD) were treated with prednisolone (1 to 2 mg/kg/day) for 3 days (from days 10 to 12 after the onset of the illness) after apparently unsuccessful treatment with intravenous immunoglobulin (IVIG, 2 g/kg/dose and additional 1 g/kg/dose). Five patients responded immediately to the first course of prednisolone infusion. One patient failed to respond to the first course of prednisolone therapy, but he did respond to the second 3-day course of therapy. None of the patients demonstrated a further progression of coronary artery dilatation or any adverse effects. Standard-dose and short-term corticosteroid therapy therefore appears to be a safe and effective treatment for patients with IVIG-resistant KD.

MeSH terms

  • Child
  • Child, Preschool
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Drug Resistance*
  • Female
  • Follow-Up Studies
  • Humans
  • Immunoglobulins, Intravenous / administration & dosage*
  • Infant
  • Infusions, Intravenous
  • Male
  • Mucocutaneous Lymph Node Syndrome / diagnosis*
  • Mucocutaneous Lymph Node Syndrome / drug therapy*
  • Mucocutaneous Lymph Node Syndrome / immunology
  • Prednisolone / administration & dosage*
  • Prospective Studies
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Immunoglobulins, Intravenous
  • Prednisolone